NuCana plc (NCNA)

Market Cap	4.98M
Revenue (ttm)	n/a
Net Income (ttm)	-34.85M
Shares Out	3.93M
EPS (ttm)	-15.52
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	41,059
Open	1.270
Previous Close	1.260
Day's Range	1.250 - 1.286
52-Week Range	1.225 - 19.400
Beta	0.98
Analysts	Buy
Price Target	25.00 (+1,868.66%)
Earnings Date	Nov 25, 2024

About NCNA

NuCana plc, a clinical-stage biopharmaceutical company, engages in the development of medicines to treat patients with cancer. It applies its ProTide technology to transform prescribed chemotherapy agents and nucleoside analogs into medicines. The company, through its technology, is developing ProTides medicines to overcome the limitations of nucleoside analogs and generate much higher concentrations of anti-cancer metabolites in cancer cells. Its pipeline includes NUC-3373, a chemical entity derived from the nucleoside analog 5-fluorouracil th...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Sep 28, 2017
• Employees: 28
• Stock Exchange: NASDAQ
• Ticker Symbol: NCNA
• Website: https://www.nucana.com

Financial Performance

Financial numbers in GBP

Analyst Forecast

According to 2 analysts, the average rating for NCNA stock is "Buy." The 12-month stock price forecast is $25.0, which is an increase of 1,868.66% from the latest price.

Price Target

$25.0

(1,868.66% upside)

Analyst Consensus: Buy